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I. ABSTRACT
Cocaine and other dopamine transporter (DAT) inhibitors block synaptic
dopamine uptake by binding to the DAT. Cocaine, a powerful psychostimulant,
potentiates the dopamine mediated signal transduction in the reward areas of the
brain resulting in physical dependence on the drug.

Amphetamines are

psychotomimetics that act as substrates at the DAT and potentiate dopaminergic
neurotransmission leading to addiction.

It was previously reported that a

conservative glutamate-for-aspartate substitution in transmembrane 1 domain of
the rat DAT protein (D79E) significantly decreased the binding affinities of
several classical DAT inhibitors, but had little or no effect on the dopamine
uptake inhibition potencies (DUIPs) of these blockers. This finding implied that
different DAT sites/conformations/populations may be responsible for dopamine
uptake and for high affinity binding of inhibitors. In the present study, the DUIPs
of cocaine and other DAT ligands at wildtype DAT CHO cells fluctuated as a
function of cell age, while their binding affinities remained static.

Curiously,

neither the DUIP nor the binding affinity of amphetamine fluctuated with cell age.
The DUIP fluctuations of cocaine also extended to the N2A neuronal cells,
demonstrating its physiological relevance. The loss of correlation between DUIP
and binding affinity at DAT might be a unique property of DAT blockers that is not
exhibited by DAT substrates. A plausible explanation for the DUIP fluctuations
with cell age is the existence of two different DAT populations on the cell surface,
the relative distribution of which changes with cell age under the influence of
intracellular events such as DAT-protein interactions or alterations in the

2
phosphorylation state.

Several proteins interact with the N- and C-terminal

regions of the DAT. Studies employing GFP fusion polypeptides of the DAT Nor C-terminal fragments, which would act as decoys by intercepting DAT
modulators, showed that the DAT N- or C-terminal interactions with intracellular
proteins do not appear to be responsible for the DUIP shift.

The role of

phosphorylation state changes of DAT in DUIP fluctuations was also
investigated. Studies employing a mutant DAT lacking the first 20 N-terminal
amino acids demonstrated that N-terminal phosphorylation of DAT, specifically
involving the first five serines is not associated with the DUIP shift.
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II. INTRODUCTION

A. Overview
Dopamine (3,4-dihydroxyphenylethylamine) is a major catecholamine
neurotransmitter in the brain that plays an important role in brain processes that
control locomotor activity, reward, attention and cognition (Schultz, 2002). It is
synthesized in the neurons from the amino acid tyrosine and stored in the
synaptic vesicles. In response to a presynaptic action potential, dopamine is
released into the synaptic cleft by exocytosis, where it binds to the presynaptic
and postsynaptic dopamine receptors (Figure 1).
HO

NH 2

HO

Dopamine
The dopamine transporter (DAT) protein mediates the reuptake of
dopamine into the presynaptic neuron and is primarily responsible for regulating
the intensity and duration of the dopaminergic neurotransmission.

DAT is

considered a specific marker of dopaminergic neurons in the central nervous
system and is found in dendrites, perikarya, axons and nerve endings (Nirenberg
et al., 1996, 1997). It is the site of action of psychostimulants such as cocaine,
and neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
DAT has been implicated in the etiology of several neurological and psychiatric
conditions such as Parkinson’s disease, schizophrenia, Tourette’s syndrome,
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depression, attention deficit hyperactivity disorder (ADHD) and drug addiction
(Torres, 2006; Bannon, 2005).
Several dopamine-mediated pathways exist in the brain. The mesolimbic
and the mesocortical pathways play key roles in reward assessment.
Dopaminergic projections from the ventral tegmental area (VTA) to the limbic
areas (nucleus accumbens, ventral striatum and amygdala) comprise the
mesolimbic pathway and projections from the VTA to the cortex (medial,
prefrontal, cingulated and entorhinal cortex) comprise the mesocortical pathway
(Marsden, 2006). Other pathways include the nigrostriatal pathway (substantia
nigra to the caudate putamen) that is associated with locomotor activity and the
tuberoinfundibular pathway (hypothalamus to the pituitary) that is associated with
inhibition of prolactin release.
Cocaine is an alkaloid, extracted from the leaves of the coca plant
(Erythroxylon coca).

It is the most potent stimulant of natural origin and is

categorized as a Schedule II drug. Cocaine inhibits synaptic dopamine uptake
by interfering with DAT function.

It blocks the reuptake of dopamine into

presynaptic neurons resulting in increased synaptic dopamine concentrations
(Figure 1). Amphetamines are another class of drugs with high potential for
abuse and addiction.
amphetamine in the U.S.

Methamphetamine is the most commonly used
Amphetamines increase the synaptic dopamine

concentrations by a mechanism different from that of cocaine. They act as DAT
substrates and compete with dopamine for reuptake into the presyaptic neuron
(Figure 1).

Amphetamines also cause DAT-mediated dopamine efflux by
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reversal of the transporter. The inward transport of amphetamine by the DAT
increases the number of “inward-facing” transporter binding sites and thereby
increases the rate of outward transport of dopamine (Kahlig and Galli, 2003). A
recent study has implicated a channel-like mode of the DAT in amphetaminemediated dopamine efflux (Kahlig et al., 2005). Amphetamines also act as weak
bases at the vesicular monoamine transporters (VMAT) and release the vesicular
dopamine stores, resulting in increased intracellular dopamine concentrations
that also contribute to reverse transport.

The resultant potentiation of

dopaminergic neurotransmission in the reward areas of the brain is associated
with psychostimulant addiction.
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Dopamine
Cocaine
Amphetamine
Synaptic Vesicles
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Dopamine
Transporter

Postsynaptic
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Dopamine Receptors

Figure 1. Modulation of the dopaminergic neurotransmission by psychostimulants.
Dopamine, synthesized in the presynaptic neuron, is stored in the synaptic vesicles.
Following the arrival of an action potential, dopamine is released into the synaptic cleft by Ca2+ mediated exocytosis. Dopamine binds to the dopamine receptors on the postsynaptic neurons
and transmits neuronal signals. Neurotransmission is terminated primarily by reuptake of
dopamine into the presynaptic neuron via the DAT. Cocaine blocks the dopamine reuptake and
increases synaptic dopamine concentrations. Besides competing with dopamine for reuptake,
amphetamine promotes dopamine efflux.
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B. Statement of the Problem
Cocaine abuse and addiction remains a major problem in the U.S.
According to the 2004 National Survey on Drug Use and Health, approximately
34.2 million Americans have experimented with cocaine. There are more than
2.5 million chronic cocaine users and around 3 million occasional cocaine users
in the U.S. The tolerance factor of cocaine leads to compulsive and addictive
use within the first few uses. Even after long periods of abstinence, the memory
of euphoria associated with cocaine can trigger tremendous craving and relapse
to drug use. Cocaine addiction is rapidly progressive and can lead to severe
medical, psychiatric, and psychosocial problems. It can even contribute to the
spread of human immunodeficiency virus (HIV) infections, as a consequence of
needle sharing. The euphoria associated with cocaine use is reported to be
intensely

pleasurable

and

results

from

the

mesolimbic

dopamine

neurotransmission. The DAT has remained a primary target, with interactions at
serotonin transporter (SERT) and norepinephrine transporter (NET) playing a
secondary role, in cocaine abuse and addiction.

There are no effective

medications currently available to treat cocaine addiction.

Drugs touted as

therapies for cocaine addiction have proven to be addictive themselves. It would
be beneficial to identify a compound that blocks cocaine’s binding to the DAT
while allowing dopamine reuptake. No crystallographic or high resolution data
are available for any of the mammalian neurotransmitter transporter proteins.
Molecular 3-D models of the DAT have been developed based on sequence
homology with other protein families and data from site-directed mutagenesis
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studies. Therefore, definitive information about the conformation of the DAT or
the binding sites of the DAT ligands is not available.
It was previously demonstrated that replacement of the aspartic acid
residue at position 79 in transmembrane domain (TM) 1 of rDAT with glutamic
acid (D79E) significantly decreased binding affinities of certain DAT inhibitors,
while dopamine uptake inhibition potencies (DUIPs) remained unaffected. Thus,
the point mutation decoupled the binding affinities of the DAT blockers from their
respective DUIPs (Wang et al., 2003). In the course of the above study, it was
observed that the DUIP of cocaine at wildtype (WT) DAT fluctuated over a wide
range. Moreover, the DUIP of cocaine did not match its binding affinity value at
the WT DAT. Several studies record a similar loss of correlation between DUIP
and binding affinity of cocaine at the WT DAT (Pristupa et al., 1994; Eshleman et
al., 1999; Wang et al., 2003). Cocaine DUIP values differ by several fold at the
WT DAT as a function of the assay conditions (Reith and Coffey, 1994;
Eshleman et al., 1999). Considering the fact that the same stably transfected
WT DAT CHO cell line and similar assay conditions were employed in all the
experiments, similar DUIP values for cocaine would be expected. One of the
factors that differed between the assays was the cell passage number.
Therefore, the nature of the DUIP fluctuation phenomenon was investigated by
studying the influence of cell passage number on the DUIP of cocaine. The
DUIP fluctuation phenomenon was further characterized by studying whether this
phenomenon extended to the other DAT blockers and DAT substrates.

The

physiological relevance of the DUIP fluctuation phenomenon was also
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investigated.

The specific hypothesis to be tested here is that the DUIP of

cocaine and other DAT ligands at WT DAT fluctuates as a function of cell
passage.
Studies were extended further to identify the factors responsible for the
DUIP fluctuation.

DAT inhibitors may have more than one binding site with

different affinities at each site (Madras et al., 1989; Boja et al., 1991; Boja et al.,
1992; Rothman et al., 1994; Reith and Coffey, 1994; Gracz and Madras, 1995).
Two distinct inhibitor-binding DAT conformations or populations may exist and
the DAT conformation or population responsible for inhibitor high-affinity binding
may be less responsible for dopamine uptake (Wang et al., 2003). DAT function
and trafficking can be regulated by several factors such as protein-protein
interactions, oligomerization state of the transporter and posttranslational
modifications. Several proteins have been shown to interact with the N- and Cterminus of DAT (reviewed in Torres et al., 2006). The specific hypothesis to be
tested here is that intracellular factors interacting with the DAT N- or C-terminus
are responsible for the DUIP fluctuation of cocaine at the WT DAT.
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C. Literature Review
1. Structure of the DAT
DAT belongs to the Na+/Cl--dependent family of neurotransmitter
transporters, also referred to as the neurotransmitter:sodium symporter (NSS)
family. This family includes the transporters for biogenic amines (norepinephrine,
serotonin and dopamine), amino acids (GABA, glycine, proline and taurine) and
osmolytes (betaine and creatinine). A 620 (human) or 619 (rat) amino acid DAT
sequence is predicted from cloned cDNAs (Kilty et al., 1991; Giros et al., 1992)
with an apparent molecular mass of approximately 80,000 daltons (Patel et al.,
1994). DAT is composed of 12 transmembrane (TM) domains connected by
alternating intracellular and extracellular loops, with the N- and C-termini located
on the intracellular side of the membrane (Edvardsen and Dahl, 1994; Nirenberg
et al., 1996; Hersch et al., 1997). It has a large second extracellular loop that
has potential N-glycosylation sites (Vandenbergh et al., 1992; reviewed in Surratt
et al., 1993). Stability and plasma membrane trafficking of the DAT is strongly
influenced by glycosylation (Reith et al., 1997).
Approaches such as site-directed mutagenesis, chimeric transporters and
substituted cysteine accessibility method (SCAM) have been extensively
employed to identify the residues and the domains that participate in substrate
binding and translocation, and inhibitor binding. The rat DAT (rDAT) amino acids
F69, F105, F114, F155, T285, F319, F331, P394, F410, S527, F530, Y533, and
S538 and the human DAT (hDAT) amino acids V55 and S528 appear to be
involved selectively with substrate uptake or efflux (reviewed in Volz and Schenk,
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2005). Substitution of F69, F331 and F530 by alanine decreases the Km and
Vmax of dopamine uptake (Lin et al., 1999). Mutation of P394 to alanine does not
affect plasma membrane expression, dopamine uptake or WIN 35,428 binding
but does affect the apparent affinity of dopamine efflux at the DAT (Lin et al.,
2000a, Itokawa et al., 2002). Substitution of S528 by alanine increases the efflux
of intracellular dopamine at the DAT without affecting the Km and Vmax of
dopamine uptake (Chen and Justice, 2000). Mutation of Y533 has been reported
to selectively reduce the Vmax of dopamine uptake at the DAT (Itokawa et al.,
2000). Substitution of V55 by alanine decreases the Km for dopamine uptake at
the DAT (Lin and Uhl, 2003).
Na+ and Cl- are transported as co-substrates along with dopamine. W84
and D313 have been implicated in controlling the ability of Na+ to drive the DAT
between inward- and outward facing conformations (Chen et al., 2002; Chen et
al., 2003). Reports provide evidence for the role of N85 and N466 in Cl- binding
(Edvardsen and Dahl, 1994; Syringas et al., 2000).
rDAT amino acids residues W84, F154, P235, F252, S253, P287, F361,
F456, F542, P544, and P545 and the hDAT amino acids W84, N182 and F168
may be involved selectively with cocaine analog binding (reviewed in Volz and
Schenk, 2005).

Substitution of F154, F252, F361, F456, F542 by alanine

decreases WIN 35,428 binding affinities at the DAT (Itokawa et al., 2000; Lin and
Uhl, 2002; Lin et al., 1999). Substitution of F168 by leucine does not affect
dopamine uptake at the DAT but increases WIN 35,428 binding (Lee et al.,
2000).

The W84A mutation increases WIN 35,428 binding affinity without
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decreasing dopamine uptake affinity, suggesting that this tryptophan may
sterically hinder the binding of cocaine analogs at the DAT (Lin et al., 2000b).
Substitution of P235, P287, P544, P545 by alanine reduces WIN 35,428 binding
without affecting dopamine uptake affinities (Lin and Uhl, 2002; Lin et al., 2000a).
Mutation of S253 decreases WIN 35,428 binding affinity without affecting
dopamine uptake (Itokawa et al., 2000). Substitution of the N182 by histidine
does not affect dopamine uptake but does increase WIN 35,428 binding at the
DAT (Lee et al., 2000).

Extracellular

1

2

3

4

5

6

7

8

9

10

11

12

NH2

Intracellular

HOOC

Figure 2. Topology of the dopamine transporter.
The dopamine transporter has 12 transmembrane domains with the N- and C-termini
located on the intracellular side of the membrane. The large second extracellular loop has
several sites for glycosylation.
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Recently, the crystal structure of a bacterial leucine transporter from
Aquifex aeolicus (LeuTAa), a homologue of the NSS family of transporters, has
been reported (Yamashita et al., 2005). This high resolution structure of LeuTAa
may be very useful in understanding the structure and function of the DAT and
other mammalian transporters in the NSS family.

2. Mechanism of Dopamine Reuptake
The dopamine reuptake process is driven by coupling dopamine influx
with the inward flow of Na+ and Cl- as these ions move down a gradient across
the cell membrane. The Na+ gradient is generated by the Na+K+-ATPase (Giros
et al., 1992). DAT promotes the transport of dopamine together with Na+ and Clions

as

co-substrates

with

a

stoichiometric

ratio

of

2:1:1

for

sodium:chloride:dopamine (Chen and Reith, 2003). According to the alternating
access transport mechanism, binding of dopamine, Na+ and Cl- to DAT on the
extracellular side induces a conformational change in the transporter allowing the
exposure of the binding site to the intracellular side of the membrane. Dopamine
and the ions are translocated into the cell and the empty transporter returns to
the outward facing conformation to initiate another transport cycle. Reorientation
of SERT to its outward facing conformation requires binding and outward
transport of intracellular K+ (Rudnick, 1997). In addition to the classic substrate
transport

mechanism,

transporters

can

exhibit

channel-like

activity.

Simultaneous measurement of dopamine transport-associated current and
dopamine flux in hDAT-expressing Xenopus oocytes revealed that charge
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movement during substrate translocation was greater than would be expected for
-

a transport mechanism with fixed stoichiometry of 2 Na+ and 1 Cl ions per
dopamine molecule.

Besides the transport-associated current, hDAT also

mediates a constitutive leak current, the voltage and ionic dependencies of which
differ markedly from those of the transport-associated current (Sonders et al.,
1997).

Recent studies also provide evidence for the existence of a chloride

channel within the DAT (Ingram et al., 2002; Carvelli et al., 2004).

Extracellular
+

K

Cl

+

Na

ATP

Cl

-

DA

+

Na

-

Intracellular

Figure 3. Dopamine transport via the DAT.
The Na+K+-ATPase (pink) generates the Na+ and K+ gradients across the plasma
membrane by moving three Na+ ions out of, for every two K+ ions into, the cell. The resultant
transmembrane electric potential (negative inside) leads to Cl- redistribution. The DAT (green)
translocates one dopamine molecule along with two Na+ ions and one Cl- ion as co-substrates in
one transport cycle.
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3. DAT Inhibitors and Substrates
Cocaine is a tropane derivative that binds to the dopamine transporter
and inhibits dopamine uptake. Cocaine binds to the NET and SERT in addition
to DAT (Giros and Caron, 1993); serotonergic mechanisms may also play a role
in cocaine addiction (Rocha et al., 1998). However, decades of studies have
established that binding of cocaine to the DAT is primarily responsible for its
reward and reinforcement effects (Kuhar, 1992; Wise, 1996). A study employing
a knockin mouse line carrying a triple mutant (L104V/F105C/A109V) of the DAT
that is functional but insensitive to cocaine inhibition showed that blockade of the
DAT is necessary for cocaine reward (Chen et al., 2006). Cocaine can augment
dopamine release by mobilizing a synapsin-dependent reserve pool in mice.
Synapsins are phosphoproteins that interact with the surface of synaptic vesicles
and segregate synaptic vesicles into the reserve pool. Secretory vesicles can
exist as a releasable pool that is available for immediate exocytosis and a
reserve pool that is spatially segregated and mobilized after prolonged synaptic
activity (Pieribone et al., 1995; Duncan et al., 2003). Pretreatment with α-methylp-tyrosine, which depletes the readily releasable pool of dopamine, did not affect
cocaine’s ability to augment dopamine release. However, the mechanism by
which cocaine promotes this synapsin-mediated dopamine release is unknown
(Venton et al., 2006).
Several analogs of cocaine have been synthesized. WIN 35,428 (12 βcarbomethoxy-3β-(4-fluorophenyl)-tropane)
extensively used in DAT binding assays.

is

a

cocaine

analog

that

is

Other drugs classified as DAT
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inhibitors and employed in the present work include mazindol, methylphenidate
benztropine and the amphetamines.
Mazindol, an imidazoisoindol derivative, is a tricyclic compound that binds
to all the monoamine transporters and inhibits substrate uptake. Studies have
shown that mazindol exhibits addictive potential (Chait et al., 1987). It is clinically
used as an anorexiant for the management of obesity and as an orphan drug for
the treatment of Duchenne muscular dystrophy.
Methylphenidate (Ritalin®) is typically used in the symptomatic treatment
of ADHD. Its binding affinity for the DAT is almost two times higher than that of
cocaine and exhibits reinforcing effects similar to cocaine but much milder
(Bergman et al., 1989).
Benztropine (3α-diphenylmethoxytropane; Cogentin®) and its analogs
have high affinity for the dopamine transporter and inhibit dopamine uptake but
demonstrate behavioral profiles that are distinctive from cocaine. Benztropine
differs from cocaine in that it has a diphenylmethoxy group attached to the C-3
position of the tropane ring (Newman and Kulkarni, 2002). It is an anticholinergic
agent that is clinically used in the treatment of Parkinsonism. Benztropines are
being extensively studied as potential agents in the treatment of cocaine
addiction.
Amphetamines (alpha-methylphenethylamines) are structurally similar to
dopamine and act as substrates at the dopamine transporter.
amphetamines

include

(+)-amphetamine,

Examples of

methamphetamine,

3,4-

methylenedioxymethamphetamine (MDMA; ecstasy). Though amphetamines act

17
at the NET and the SERT, the interaction of amphetamines with the DAT is
thought to mediate the acute behavioral and reinforcing effects of these
psychostimulants (Giros et al., 1996). Amphetamines are used in the treatment
of ADHD and narcolepsy.
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O

H3C
O
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O

N

N
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CH3
Benztropine
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N

HO
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Cl

Mazindol

Methylphenidate

CH3
NH2
Amphetamine
Figure 4. Chemical structures of DAT ligands.
Cocaine, benztropine, methylphenidate and mazindol are DAT blockers. Amphetamine is
a DAT substrate.
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DAT expression at the cell surface can be regulated by DAT substrates
and inhibitors.

In both HEK 293 cells expressing hDAT and in rat striatal

synaptosomes, persistent exposure to dopamine (1 hr) decreased DAT surface
expression and dopamine uptake activity.

The presence of cocaine during

dopamine pretreatment prevented the down-regulation of surface DAT.

This

suggests that dopamine translocation by the DAT is a prerequisite for the
dopamine-mediated decrease in surface expression of DAT (Chi and Reith,
2003). In HEK 293 cells and N2A cells stably expressing hDAT, acute treatment
with cocaine (≥ 5 min) increased DAT surface expression and dopamine uptake
activity.

Similar results were obtained with synaptosomes prepared from the

nucleus accumbens of rats sacrificed 30 minutes after a single cocaine injection
(Daws et al., 2002; Little et al., 2002). Persistent exposure to amphetamine (> 20
min) decreases DAT surface expression and dopamine uptake activity (Gulley et
al., 2002; Saunders et al., 2000; Zahniser and Sorkin, 2004). A recent study
showed that amphetamine increases the DAT surface expression rapidly within
one minute by recruiting more transporter proteins to the plasma membrane
(Johnson et al., 2005a).
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4. Regulation of DAT Function and Expression
DAT Oligomerization
Increasing evidence suggests that the NSS family members are organized
into

oligomeric

complexes.

Coimmunoprecipitation

studies

employing

differentially tagged monomers demonstrated that SERT and NET can exist as
homo-oligomers (Kilic and Rudnick, 2000; Kocabas et al., 2003). Fluorescence
resonance energy transfer (FRET) studies provided evidence for the homooligomerization of SERT and GABA transporter (Schmid et al., 2001). Similar to
other transporters of the NSS family, DAT also exists as an oligomeric complex
and oligomerization may be essential for the proper trafficking of the DAT to the
plasma membrane. Two loss-of-function DAT mutants (Y335A and D79G) that
expressed at the cell surface decreased the transport activity of WT DAT without
affecting its cell surface expression. This suggested the formation of oligomeric
complexes of WT DAT with the DAT mutant at the cell surface. The same study
showed that an intact leucine heptad repeat in the TM2 domain of the DAT is
required for oligomerization.

Substitution of amino acids in this repeat by

mutagenesis resulted in a mutant transporter devoid of uptake activity because of
its intracellular retention. This mutant did not inhibit the function of the WT DAT.
Coimmunoprecipitation and immunofluorescence studies demonstrated that an
HA epitope-tagged DAT with the leucine heptad repeat mutation did not
associate with a histidine epitope-tagged WT DAT (Torres et al., 2003). DAT can
be oxidatively cross-linked to form homodimers that retain transporter
functionality; the cross-link is between C306 at the extracellular end of TM6 in
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each of the two DAT molecules (Hastrup et al., 2001). The intracellular end of
TM6 domain of the DAT has a dimerization motif (GV/IXXGV/IXXA/T) that is
found in other neurotransmitter proteins as well.

This motif was originally

identified in glycophorin A and was found to be essential for dimerization.
Mutation of the first glycine of the dimerization motif to valine greatly diminished
DAT surface expression and completely blocked substrate transport. Mutation of
the second glycine completely inhibited surface expression. Hence, a functional
dimerization motif in the TM6 domain of the DAT is essential for efficient
trafficking of the transporter.

The data suggested that the TM6 domain

contributes to the dimerization interface and that oligomerization may be required
for cell surface trafficking (Hastrup et al., 2001).

Studies employing FRET

revealed that DAT exists as oligomers in all cellular compartments in which it is
localized (Sorkina et al., 2003). DAT can also exist as tetramers and the TM4
(C243) domain is present at a homodimeric interface distinct from the TM6
(C306) interface (Hastrup et al., 2003). The same study also showed that DAT
inhibitors such as the cocaine analog MFZ 2-12, benztropine and mazindol
disallowed the cross-linking of C243 suggesting that these uptake inhibitors are
not simply neutral blockers but by themselves produce conformational changes
of the DAT. Oligomerization of the DAT protein may thus play an important role
in the proper functioning and trafficking of the transporter.
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Posttranslational Modifications
DAT is a heavily glycosylated protein with three or four potential
consensus sequences (depending on species) for N-linked glycosylation (sugars
are attached to the amide nitrogen of asparagine residues) in the large second
extracellular loop.

In general, N-linked glycosylation is essential for proper

folding and stability of proteins. Differences in apparent molecular mass of the
DAT were observed in the striatal tissue of 4, 14 and 60 day old rats. These
differences were eliminated by N-deglycosylation suggesting that differential
glycosylation of DAT occurs during development and aging (Patel et al., 1994).
Alterations in the glycosylation pattern of DAT were also observed in different
brain regions (nucleus accumbens versus striatum) and in different species (Lew
et al., 1991; Patel et al., 1993).

Non-glycosylated DAT does not transport

dopamine as efficiently as WT DAT. A sharp reduction in dopamine uptake Vmax
greater than that accounted for by the fall in surface DAT levels was observed
with DAT mutants lacking the glycosylation sites (N181, N188 and N205).
Inhibiting DAT N-glycosylation increased the DUIP of cocaine-like drugs without
changing their affinity for the DAT (Li et. al., 2004). Removal of the three hDAT
glycosylation sites partially impaired DAT trafficking to the plasma membrane,
suggesting that glycosylation increases DAT surface expression but is not
essential for trafficking to the cell surface (Torres et al., 2003).

Confocal

microscopy studies demonstrated that the immunofluorescence of the single
mutant N181Q was mostly on the cell surface, similar to the WT DAT. However,
the immunofluorescence of the double (N181Q, N188Q) and triple mutants
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(N181Q, N188Q, N205Q) was weaker at the cell surface, with a significant
amount in the cytosol.

Reversible biotinylation experiments to assess DAT

endocytosis showed that the double and triple mutants were internalized at a
faster initial rate, with a significantly reduced surface DAT half-life (Li et al.,
2004). Despite several studies, the exact role of N-glycosylation in DAT function
and cell surface expression remains unclear.

It has been shown that N-

glycosylation of SERT is important for homo-oligomerization and protein
interactions that regulate serotonin uptake (Ozaslan et al., 2003).

Similar to

SERT, changes in the DAT N-glycosylation pattern may affect DAT-protein
interactions leading to differences in transporter function and trafficking.
Analysis of the DAT primary amino acid sequence reveals that the protein
has several consensus sites for phosphorylation by protein kinase A (PKA),
protein kinase C (PKC) and Ca2+/calmodulin dependent protein kinase (CaM
kinase). To date PKC is the only kinase that has been well characterized as
contributing to DAT phosphorylation. Several studies have shown that activation
of PKC results in reduced DAT activity and surface expression. Activation of
PKC by the phorbol ester 4-α-phorbol 12-myristate 13-acetate (PMA) decreased
the DAT uptake activity in Sf9 cells, evident by the decreased Vmax value. The
PMA-mediated reduction in dopamine uptake was antagonized by staurosporine,
a PKC inhibitor. Confocal microscopy studies revealed that sequestration of the
DAT from the cell surface was responsible for the decreased Vmax of dopamine
transport.

However, the DAT surface density in PMA-treated cells remained

unchanged. Treating the cells with a PKC inhibitor promoted an increase in
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dopamine uptake that was a result of recruitment of the internalized or
intracellular DAT back to the cell surface.

The data suggested that rapid

shuttling of the DAT protein between the cell surface and intracellular
compartments was responsible for the changes in dopamine transport activity in
response to PKC activation. Moreover, the differential regulation of the DAT
activity by a PKC-dependent mechanism was not a result of modifications in the
DAT catalytic activity (Pristupa et al., 1998). Another study in PC12 cells stably
transfected with hDAT demonstrated that the transporter undergoes endosomal
recycling in response to PKC activation (Melikian and Buckley, 1999). DAT is
internalized through a clathrin-mediated and dynamin-dependent mechanism in
MDCK cells, evidenced by the complete blockade of PMA-mediated translocation
of DAT with a dominant negative mutant of dynamin 1. However, this study
showed that PKC activation results in complete lysosomal degradation of the
transporter protein, inconsistent with the previous studies (Daniels and Amara,
1999). Truncation of the first 22 N-terminal amino acids, including several serine
residues, nearly abolished detectable phosphorylation of hDAT without affecting
functional regulation by PKC, suggesting that phosphorylation of these residues
is not essential for PKC-mediated transporter internalization (Granas et al.,
2003). The dopamine uptake activity, inhibitor binding and oligomerization of this
truncated DAT were also not significantly different from the full-length DAT
(Hastrup et al., 2001). DAT has a dileucine motif in the third intracellular loop
and two tyrosine-based motifs, one in the second intracellular loop and one in the
C-terminus.

These motifs play key roles in the intracellular trafficking of
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membrane proteins by mediating critical protein-protein interactions. Mutation of
the dileucine motif and the two tyrosine-based trafficking motifs in hDAT did not
significantly affect the PKC-mediated internalization, suggesting that PKCmediated internalization does not involve these trafficking motifs (Granas et al.,
2003). A recent study showed that the PKC-regulated endocytic signal resides in
the C-terminal region (amino acids 587-591; FREKL) of the DAT (Holton et al.,
2005).

Mitogen-activated protein kinase (MAPK) has also been shown to

regulate the DAT uptake activity and trafficking.

Striatal synaptosomes and

epitope tagged hDAT HEK 293 cells exhibited decreased Vmax values without any
change in Km values when incubated with MAPK kinase (MEK) inhibitors.
Biotinylation and confocal studies demonstrated that the decrease in Vmax was a
result of the internalization of surface DAT by clathrin-mediated endocytosis
(Moron et al., 2003).
Substrates such as amphetamine and methamphetamine can also
increase DAT phosphorylation in the absence of exogenous kinase or
phosphatase. Cocaine and the PKC inhibitor bisindoylmaleimide were able to
inhibit methamphetamine-induced DAT phosphorylation (Cervinski et al., 2005).
Incubation with cocaine, mazindol or methylphenidate did not affect basal or
PMA-stimulated DAT phosphorylation, but GBR12909 (another DAT blocker)
strongly suppressed PMA-stimulated phosphorylation (Gorentla and Vaughan,
2005). Thus, DAT ligands can have different effects on DAT phosphorylation.
The only process identified to date as requiring DAT phosphorylation is
substrate-induced dopamine efflux (Khoshbouei et al., 2004; Johnson et al.,
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2005b).

In HEK 293 cells stably expressing an N-terminal truncated DAT

(lacking the first 22 amino acids) amphetamine-induced dopamine efflux was
significantly reduced compared to the full-length DAT. To investigate the role of
N-terminal phosphorylation of the DAT in dopamine efflux, all five N-terminal
serine residues were simultaneously mutated to alanines.

Surprisingly, this

construct significantly impaired amphetamine-induced dopamine efflux, similar to
the N-terminal truncated DAT. In contrast, simultaneous mutation of these same
five serines to aspartate to simulate phosphorylation resulted in normal
amphetamine-induced dopamine efflux. However, the Vmax for dopamine uptake
remained unaltered in all the mutants. The study suggests that the N-terminal
phosphorylation of the DAT is essential for amphetamine-induced dopamine
efflux but does not affect the inward transport of substrate (Khoshbouei et al.,
2004). These results could lead to the design and synthesis of new therapeutic
agents, such as drugs that inhibit amphetamine-induced dopamine efflux without
affecting dopamine uptake.

Protein Interactions
Compelling evidence has shown that the DAT undergoes regulated
trafficking, indicating the possible involvement of transporter-interacting proteins.
Moreover, several proteins have been implicated in DAT-protein interactions that
influence the cell surface expression and/or function of the DAT (reviewed in
Torres, 2006).

Synuclein, a protein that is abundantly expressed in different

brain regions and highly enriched in presynaptic terminals, has been shown to
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interact with the hDAT. The direct protein-protein interaction between hDAT and
α-synuclein was found to involve the C-terminal region of hDAT (last 15 amino
acids) and the non-Aβ component (NAC) domain of α-synuclein. Co-expression
of this protein with hDAT enhanced the dopamine uptake activity and membrane
clustering of the transporter (Lee et al., 2001).

PICK1, a kinase associated

protein widely expressed in many tissues including the brain, is a member of a
family of PDZ domain containing proteins that play an important role in the
targeting and clustering of several receptors and ion channels. This protein has
been shown to interact with the C-terminal region (last 3 amino acids) of the
DAT. Overexpression of PICK1 in mammalian cells with hDAT and in cultured
neurons enhanced the DAT uptake activity due to an increase in the number of
functional transporters at the cell membrane. Deletion of the PDZ-binding site in
DAT impaired the targeting of the mutated transporter to neuronal processes in
cultured neurons (Torres et al., 2001). Hic-5, a member of the focal adhesion
family of adaptor proteins is highly expressed in several tissues including the
brain. The amino-proximal portion of the intracellular carboxyl terminus of DAT
has been shown to interact in vitro and in vivo with the LIM domain of Hic-5.
Confocal studies demonstrated that Hic-5 colocalizes with DAT on the cell
membrane.

Hic-5 overexpression downregulates DAT uptake activity by

decreasing DAT surface expression (Carneiro et al., 2002). It has been shown
that syntaxin 1A and the receptor for activated C kinase (RACK1) interact with
the DAT N-terminal region. Syntaxin 1A is a major component of the soluble Nethylmaleimide-sensitive factor attachement protein receptor (SNARE) complex
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that regulates neuronal exocytosis; RACK1 is a protein that regulates
phosphorylation (Lee et al., 2004).

The role of these protein interactions in

regulation of DAT activity and trafficking has not yet been demonstrated.
Syntaxin 1A has also been shown to interact with the related GABA transporter
(GAT1) and the NET resulting in altered surface expression and transport activity
(Horton and Quick 2001; Sung et al., 2003). Because DAT is structurally similar
to these transporters, it is likely that syntaxin also regulates DAT uptake activity
and trafficking. Parkin, a protein expressed exclusively in dopaminergic neurons
is associated with Parkinson’s disease (PD). Parkin contains a protein-ubiquitin
E3 ligase that ubiquitinates many substrate proteins to enhance their
degradation. Parkin, but not its PD-causing mutants, increased dopamine uptake
at DAT by increasing its cell surface expression.

Parkin enhanced the

ubiquitination and degradation of misfolded DAT, so as to prevent it from
interfering with the oligomerization and cell surface expression of native DAT.
Thus, it indirectly increased the cell surface expression of the functional DAT
(Jiang et al., 2004).
Characterizing the DUIP fluctuation phenomenon of cocaine and other
DAT ligands and identifying the factor/s responsible for such potency fluctuations
can help understand better the regulation of DAT activity. Specific Aim 1 is to
study whether DAT ligands that inhibit DA uptake show DUIP fluctuations at WT
DAT as a function of cell age. It also involves investigation of the physiological
relevance of the DUIP fluctuation phenomenon. Specific Aim 2 is to investigate
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the source of the DUIP fluctuation by assessing the role of the N- or C- terminus
of the DAT.
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III. MATERIALS AND METHODS
A. Materials and Equipment
1. Facilities
Laboratories – Mellon Hall of Science, Rooms 456, 414 and 214

2. Cell Lines
Chinese Hamster Ovary (CHO) cells stably transfected with wildtype DAT
Dr. Surratt’s laboratory at Albert Einstein College of Medicine, NY
COS-7 (African green monkey kidney) cells
American Type Culture Collection (ATCC), Manassas, VA
N2A (murine neuroblastoma) cells
Dr. Gnegy’s laboratory at University of Michigan, MI
3. Chemicals and Drugs
[3H]-Dopamine
Perkin Elmer, Foster City, CA
[3H]-WIN 35, 428
Perkin Elmer, Foster City, CA
Acetic acid, glacial
Fisher Scientific, Pittsburgh, PA
Agarose
Invitrogen Corporation, Carlsbad, CA
Alexa-Fluor 488, goat anti-rat IgG (H+L)
Molecular Probes, Eugene, OR
Ampicillin sodium salt
Acros, NJ
Bio-Rad protein assay dye reagent concentrate
Bio-Rad Laboratories Inc., Hercules, CA
Bovine serum albumin
Sigma Chemical Co., St. Louis, MO
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Calcium chloride
Sigma-Aldrich Co., St. Louis, MO
Compressed carbon dioxide
Air Products, Pittsburgh, PA
D-(+)-Glucose
Sigma-Aldrich Co., St. Louis, MO
dNTP mix
Stratagene, La Jolla, CA
DH5α cells
Invitrogen, Carlsbad, CA
Dimethylsulfoxide (DMSO)
Sigma Chemical Co., St. Louis, MO
Dulbecco’s Modified Eagle Medium (DMEM)
Hyclone, Logan, UT
Dulbecco’s Phosphate Buffered Saline (DPBS) Ca/Mg-free
Cambrex Bioscience Walkersville Inc., MD
EcoR1
Invitrogen, Carlsbad, CA
EDTA
Sigma-Aldrich Co., St. Louis, MO
Ethanol 200 proof
Pharmaco Products Inc., Brookfield, CT
Ethanol, HPLC grade
Acros, NJ
Ethidium bromide
Fisher Scientific, Pittsburgh, PA
F-12 Nutrient Mixture
Hyclone, Logan, UT
Fetal bovine serum
Hyclone, Logan, UT
G-418 sulfate
Clontech Laboratories Inc., CA
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L-Glutamine
Invitrogen, Carlsbad, CA
Glycerol
Fisher Scientific, Pittsburgh, PA
Glycine
Sigma-Aldrich Co., St. Louis, MO
Goat serum
Biomeda Corporation, Foster City, CA
GVA mounting solution
Zymed, San Francisco, CA
HEPES free acid
MP Biomedicals Inc., Solon, OH
HBSS/modified
Hyclone, Logan, UT
Isopropanol (DNase, RNase and protease free)
Fisher Scientific, Pittsburgh, PA
Kpn1
Invitrogen, Carlsbad, CA
LB agar
Fisher Scientific, Pittsburgh, PA
LB broth
Fisher Scientific, Pittsburgh, PA
MAB369 Rat anti-Dopamine Transporter
Chemicon International, Temecula, CA
Methanol, HPLC grade
Fisher Scientific, Pittsburgh, PA
Opti-MEM I
Invitrogen, Carlsbad, CA
Paraformaldehyde
Sigma Chemicals Co., St. Louis, MO
Penicillin-Streptomycin
Gibco-BRL, Grand Island, NY
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PolyFect Transfection Reagent
Qiagen Inc., Valencia, CA
Polymerase, Pfu Turbo
Stratagene, La Jolla, CA
Potassium chloride
Sigma-Aldrich Co., St. Louis, MO
Potassium phosphate, monobasic
Sigma Chemical Co., St. Louis, MO
Primers
Sigma Genosys, The Woodlands, TX
Rhodamine phalloidin
Molecular Probes, Eugene, OR
RNase A (DNase free)
Fisher Scientific, Pittsburgh, PA
SOC media
Invitrogen, Carlsbad, CA
ScintiSafe scintillation fluid
Fisher Scientific, Pittsburgh, PA
Sodium Chloride
Sigma-Aldrich Co., St. Louis, MO
Sodium Hydroxide
Fisher Scientific, Pittsburgh, PA
Sodium Hydroxide 2N solution
Fisher Scientific, Pittsburgh, PA
Sodium Hydroxide 12N solution
Fisher Scientific, Pittsburgh, PA
Sodium lauryl sulfate
Sigma Chemical Co., St. Louis, MO
T4 DNA ligase
Invitrogen, Carlsbad, CA
Tris-EDTA buffer (DNase, RNase and protease free)
Acros, NJ

33
Tris free base
Fisher Scientific, Pittsburgh, PA
Tris-HCl salt
Sigma Chemical Co., St. Louis, MO
Triton X-100
Acros, NJ
Trypsin-EDTA 10X
Gibco-BRL, Grand Island, NY
Xba1
Gibco-BRL, Grand Island, NY

4. Kits
Gel extraction kit
Qiagen Inc., Valencia, CA
PCR purification kit
Qiagen Inc., Valencia, CA
Plasmid miniprep kit
Stratagene, La Jolla, CA
Plasmid purification kit (maxiprep)
Qiagen Inc., Valencia, CA

5. Other Materials
Cell culture flasks, 75 cm2
Corning Inc., NY
Cell culture grade water
Hyclone, Logan, UT
Cell scraper, disposable
Fisher Scientific, Pittsburgh, PA
Centrifuge tubes, 15 ml
Corning Inc., NY
Cryogenic vials, 1.5 ml
Corning Inc., NY
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Culture tubes, disposable
Fisher Scientific, Pittsburgh, PA
Falcon tubes, 14 ml
Fisher Scientific, Pittsburgh, PA
Falcon tubes, 50 ml
Fisher Scientific, Pittsburgh, PA
Filter unit, sterile
Millipore Corporation, MA
Glass microscope coverslips (# 1)
Fisher Scientific, Pittsburgh, PA
Glass microscope slides
Fisher Scientific, Pittsburgh, PA
Microcentrifuge eppendorf tubes, 1.5 ml
Fisher Scientific, Pittsburgh, PA
Parafilm
Fisher Scientific, Pittsburgh, PA
Pasteur pipettes, disposable
Fisher Scientific, Pittsburgh, PA
Pipette tips, disposable Redi-Tips TM (1, 10, 200, 1000 µl)
Fisher Scientific, Pittsburgh, PA
Polaroid film
Polaroid Corporation, Cambridge, MA
Polypropylene tubes
Fisher Scientific, Pittsburgh, PA
Respirator
Fisher Scientific, Pittsburgh, PA
Scintillation vials
Fisher Scientific, Pittsburgh, PA
Serological pipettes, sterile disposable (5, 10, 25 ml)
Fisher Scientific, Pittsburgh, PA
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Syringes 10 ml, sterile
Fisher Scientific, Pittsburgh, PA
Thermowell PCR tubes
Corning Incorporated, NY
Tissue culture plates, sterile (6-well)
Fisher Scientific, Pittsburgh, PA

6. Equipment
Analytical balance
Mettler Toledo Inc., OH
Bottletop dispenser
Brinkmann Instruments Inc., NY
Cell culture incubator
Forma Scientific, MA
Centrifuge Model 228
Fisher Scientific, Pittsburgh, PA
Centrifuge 5415 C
Eppendorf Scientific Inc., NY
Centrifuge 5810 R
Eppendorf Scientific Inc., NY
Confocal laser microscope Leica TCS-SP2
Leica Microsystems Inc., PA
Dispenser eppendorf (50 ml)
Brinkmann Instruments Inc., NY
Electrophoresis Power Supply
Life Technologies Inc., Gaithersburg, MD
Horizontal Gel Electrophoresis System
Life Technologies Inc., Gaithersburg, MD
Inverted microscope Olympus CK40
Fisher Scientific, Pittsburgh, PA
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Isotemp Incubator
Fisher Scientific, Pittsburgh, PA
Lab freezers and refrigerators
Forma Scientific, MA
Liquid Nitrogen tank
Liquid Scintillation Analyzer
Packard Instruments Co., CT
Millipore Milli-Q and Elix
Millipore Corporation, MA
Mixer (Style: 37600)
Thermolyne Corporation, IA
NapFLOW Laminar air flow unit
Fisher Scientific, Pittsburgh, PA
ORBIT Shaker
Lab-line Instruments Inc., IL
PCR Mastercycler
Eppendorf Scientific Inc., NY
pH meter AB15
Fisher Scientific, Pittsburgh, PA
Pipet-aid
Drummond Scientific Co., Broomall, PA
Pipetman (P-2, P-10, P-20, P-100, P-200, P-1000)
Mettler Toledo Company, Woburn, MA
Polaroid Gelcam
Polaroid Corporation, Cambridge, MA
Stir plate Nuova II
Thermolyne Corporation, IA
Universal Vacuum System UVS 400
Savant Instruments Inc., NY
UV Transilluminator M-26
UVP Inc., Upland, CA
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UV-Visible Spectrophotometer DU 530
Beckman Instruments Inc., Fullerton, CA
Vacuum pressure pump
Barnant Co., IL
Vertex-2 Genie
Scientific Industries Inc., NY
Water bath 180 series
Precision Scientific, Winchester, VA
Water bath Iso TEMP 205
Fisher Scientific, Pittsburgh, PA
Weighing scale
Denver Instruments Co., CO

7. Computer Software
Adobe Acrobat Reader 7.0
Adobe Systems Inc.
Adobe Acrobat Writer
Adobe Systems Inc.
ChemDraw
CambridgeSoft Corporation, Cambridge, MA
GraphPad Prism 3.0
GraphPad Software, San Diego, CA
Microsoft Office Word & Excel 2003
Microsoft Corporation
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B. Methodology and Procedures

1. Cell Culture
CHO-K1 cells stably transfected with WT DAT were grown in F-12 media
supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin ,100
units/ml streptomycin and 100µg/ml G-418.

COS-7 cells were cultured in

“complete” DMEM media (supplemented with 10% FBS, 100 units/ml penicillin,
100 units/ml streptomycin and 20 mM L-glutamine). N2A cells were grown in
“complete” OPTI-MEM I media (supplemented with 10% FBS, 100 units/ml
penicillin and 100 units/ml streptomycin).

All cell types were grown as

monolayers in 75 cm2 flasks at 37ºC and 5% CO2 and subcultured twice weekly
or every 3 days.

For subculturing the WT DAT CHO and COS-7 cells, the

exhausted media in the flask was aspirated and the confluent adherent cells
were washed once with 10 ml Hanks buffered salt solution (HBSS). To detach
the cells from the flask, 3ml trypsin-EDTA was added and swirled to cover the
cell monolayer completely. Two ml of the trypsin-EDTA was aspirated and the
flask was returned to the incubator. The cells were checked every 2 minutes for
detaching from the flask. The detached cells were resuspended in 9 ml complete
media to inactivate the trypsin. Two ml of the cell suspension was transferred
into a new labeled flask containing 18 ml of complete media. The flask was
capped and the cells evenly suspended by gently swirling the flask. The flask
was placed in the incubator and the cells were allowed to grow till the next
subculture. For subculturing the N2A cells, the exhausted media in the flask was
removed and 3 ml of trypsin-EDTA was added. Two ml of the trypsin-EDTA was
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removed from the flask and the cells were incubated with the remaining 1 ml
trypsin-EDTA at room temperature (inside the sterile laminar air flow unit) for 1-2
minutes until the cells detached from the flask. The cells were resuspended in 9
ml of complete media to inactivate the trypsin.

The cell suspension was

transferred into a sterile 15 ml tube and centrifuged for 4 minutes.

The

supernatant was decanted and cell pellet was resuspended in 10 ml complete
media. Two ml of the cell suspension was transferred into a new labeled flask
containing 18 ml of complete media. The flask was capped and the cells evenly
suspended by gently swirling the flask. The flask was moved to the incubator
and the cells were allowed to grow till the next subculture.

2. Polymerase Chain Reaction and Plasmid Preparation
The N- and C-terminus fragments of rat WT DAT were generated and
amplified by Polymerase Chain Reaction. Primers were designed for the N- and
C-terminus fragments with Kpn1 and EcoR1 restriction enzyme sites on the 5'
ends of the sense and antisense primers respectively.

The sequences

of primers designed for the N-terminus (first 68 nucleotides) of WT DAT
were: 5'-ATATATGGTACCATGAGTAAGAGCAAATGCTCCGTGGGAC-3' and 5'ATATATGAATTCATCAATTTTCTTGCTCCAGGTCTCCCG-3'.

The sequences

of the primers designed for the C-terminus fragment (last 43 nucleotides) of WT
DAT were: 5'-ATATATGGTACCTACAAGTTCTGCAGCCTGCCGGGGTC-3' and
5'-ATATATGAATTCCAGCAACAGCCAGTGACGCAGCG-3'. The primers were
synthesized by Sigma Genosys Inc., U.S.A. WT DAT in Bluescript vector was
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used as the template. The reaction tubes were prepared with the calculated
quantities of template, primers, dNTP mix and Pfu Turbo DNA Polymerase. The
reaction was set for 25 cycles with denaturation of the double stranded template
DNA at 95ºC for 45 seconds, annealing of the primers to the single stranded
DNA at 55ºC for 45 seconds and extension of the new DNA strand at 72ºC for 2
minutes. Agarose gel electrophoresis was employed to confirm the right sizes of
the PCR products.

The gel purified PCR products were digested with the

restriction enzymes and ligated into pc3DNAGFP vector such that the DAT Nand C- terminus peptide fragments would be expressed with GFP tag attached to
the C-terminus of the peptide when transfected into mammalian cells.

The

ligation product was transformed into DH5α cells by heat shock method and the
cells were plated on ampicillin supplemented agar petri plates and incubated at
37ºC for 16 hours. The bacterial colonies were used to inoculate 5 ml of LB broth
and the bacteria were allowed to grow for 16 hours. The supercoiled DNA was
extracted using the Stratagene mini-prep kit and after confirming the right DNA
sequence (sequencing facility, University of Pittsburgh) and size (by digesting
with restriction enzymes and agarose gel electrophoresis), 200 ml LB broth was
inoculated to produce large amounts of the plasmid of interest.

The DNA

concentration was estimated by measuring the absorbance at 260 nm and purity
was determined by the ratio of the absorbance values at 260 and 280 nm.
Plasmid DNA with a ratio of greater than or equal to 1.7 was considered pure
enough for performing transient transfections. The pcDNA3 plasmids encoding
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human DAT (hDAT) and del-20 hDAT (hDAT lacking the first 20 amino acids)
were kindly provided by Dr. Gonzalo E. Torres, University of Pittsburgh.

3. Cell Transfections
Stably transfected WT DAT CHO cell line employed in the study was
developed in Dr. Surratt’s laboratory at Albert Einstein College of Medicine, NY.
Lipofectamine transfection method and G-418 mediated stable transfectant
selection was employed for preparing the stable cell line.
Polyfect method with modification of the manufacturer’s protocol was
employed for transiently transfecting COS-7 cells. The day before transfection, 4
х 105 cells were seeded in 6-well plates and incubated at 37ºC and 5% CO2 such
that the cells would be 50-80% confluent on the day of transfection. Prior to
transfection, the growth media in the plates was gently aspirated, the cell
monolayers were washed with 1 ml phosphate buffered saline (PBS), 1.5 ml
fresh complete media was added to the cells in each well, and the cells were
maintained at 37ºC and 5% CO2 until the addition of transfection complexes. For
preparing the transfection mixture for the cells in one well, 1.5 µg DNA was
added to 100 µl media (containing no serum, proteins, or antibiotics) in a sterile
tube and mixed by vortexing for few seconds.

Ten µl Polyfect reagent was

added to the DNA solution, mixed by vortexing for 10 seconds and incubated for
9 minutes at room temperature to allow complex formation.

Six hundred µl

complete media was added to the reaction tube containing transfection
complexes and mixed by pipetting up and down twice. The total volume of the
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transfection mix was transferred immediately to the cells in a single well and the
plate was gently swirled to ensure uniform distribution of the complexes. The
cells were then incubated at 37ºC and 5% CO2 and pharmacological assays were
performed 24 - 48 hours after transfection.

When performing transient

transfections of cells in more than one well, all the volumes were scaled up
appropriately.

In experiments manipulating the DAT expression levels,

suboptimal amounts of plasmid were employed. Vector plasmid was employed
to ensure that each well received the same amount of total DNA. In experiments
requiring co-transfection of different plasmids, the required amounts of each
plasmid were calculated and vector plasmid was employed to ensure that each
treatment supplied the same amount of total DNA to the cells.
Transient transfections with N2A cells were conducted via the modified
calcium phosphate method (Graham and van der Eb, 1973). The day before
transfection, cells were seeded in 6-well plates and incubated at 37ºC and 5%
CO2 such that the cells would be 30-40% confluent on the day of transfection.
Four hours prior to transfection, the media in the wells was replaced with 2 ml
fresh media. All the reagents were filter sterilized. The transfection procedure
involved preparing 2 tubes, with the contents of one tube added slowly to the
other. Preparing the first tube involved addition of Millipore water, plasmid DNA,
10х Tris-EDTA (TE) buffer pH 8.0 and 0.5 M CaCl2 in the order listed and mixing
by gently vortexing. The second tube contained 2x HEPES – buffered saline
(HBS) solution.

The contents of first tube were added to the second tube

dropwise with continuous gentle vortexing and incubated at room temperature.
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Soon after the DNA complexes started forming, the mixture was pipetted up and
down thrice to ensure a uniform suspension and to reduce the particle size of the
complexes. Two hundred µl of the above mixture was added to each well and
the plate was gently swirled to ensure uniform distribution. The following day, the
transfection mixture in each well was replaced with 2 ml fresh media. The cells
were used for the pharmacological assays 48 hours later.

In experiments

manipulating the DAT expression levels, suboptimal amounts of plasmid were
employed and same amount of total DNA was added to the cells by employing
vector plasmid. In experiments requiring co-transfection of different plasmids,
the required amounts of each plasmid were calculated and vector plasmid was
employed to ensure that each treatment supplied the same amount of total DNA
to the cells.

4. [3H]-Dopamine Uptake Assays
All [3H]-dopamine uptake assays were performed with cells grown in 6-well
plates. For performing simple [3H]-dopamine uptake assays, cell monolayers
were washed 2 х 1 ml with “KRH buffer” (25 mM HEPES, pH 7.3, 125 mM NaCl,
4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 5.6 mM glucose)
supplemented with 50 mM ascorbic acid (KRH/AA), incubated with 750 µl
KRH/AA buffer (total uptake) or 10 µM mazindol (non-specific uptake) for 10
minutes, followed by incubation with10 nM [3H]-dopamine for an additional 5
minutes. Uptake was quenched by washing the cell monolayers 2 х 1 ml with
KRH/AA buffer. Cell monolayers were solubilized by incubating with 1 ml of 1%
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SDS at room temperature for 1 hour with gentle shaking. The cell lysates were
transferred into scintillation vials containing 5 ml of ScintiSafe fluid and the
incorporated radioligand was determined by employing a liquid scintillation
counter. The specific uptake was calculated as the difference between total and
non-specific uptake, i.e. uptake in the presence and absence of 10 µM mazindol.
For performing [3H]-dopamine uptake inhibition assays, cell monolayers
were washed 2 х 1 ml with KRH/AA buffer, incubated with 750 µl DAT blocker or
substrate for 10 minutes, followed by incubation with10 nM [3H]-dopamine for an
additional 5 minutes. The uptake inhibition assays included nonradioactive DAT
inhibitors or substrates at the following concentration ranges: cocaine, 1nM – 100
µM; benztropine, 1 nM – 30 µM; mazindol, 0.1 nM – 10 µM; methylphenidate 3
nM – 30 µM; (+)-amphetamine, 1 nM – 10 µM.

Uptake was quenched by

washing the cell monolayer 2 х 1 ml with KRH/AA buffer. Cell monolayers were
solubilized by incubating with 1 ml of 1% SDS at room temperature for 1 hour
with gentle shaking.

The cell lysates were transferred into scintillation vials

containing 5 ml of ScintiSafe fluid and the incorporated radioligand was
determined by employing a liquid scintillation counter. Non-specific uptake was
determined by using 10 µM mazindol, or 30 µM cocaine if mazindol was the drug
being assessed. The specific uptake was calculated as the difference between
total and non-specific uptake.

The IC50 values for [3H]-dopamine uptake

inhibition were determined with GraphPad Prism 3.0.
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5. Ligand Binding Assays
All ligand binding assays were performed with cells grown in 6-well plates.
All [3H]-WIN 35,428 binding inhibition assays were performed exactly as
described above for the dopamine uptake inhibition assays except that 1 nM [3H]WIN 35,428 was used in place of [3H]-dopamine, and the cells were incubated
with a mixture of radioligand and the nonradioactive competitor for 15 minutes.
One nM final concentration of [3H]-WIN 35,428 was achieved by adding 10 nM
solution to each dilution of the nonradioactive competitor. The concentration
ranges of the different nonradioactive DAT inhibitors or substrates employed in
the binding assays were as indicated above for the dopamine uptake inhibition
assays. Non-specific uptake was determined by using 10 µM mazindol or 30 µM
cocaine if mazindol was the drug being assessed. [3H]-WIN 35,428 saturation
binding assays were performed by incubating the cells with a mixture of
nonradioactive WIN 35,428 (1nM – 10 µM) and 1 nM [3H]-WIN 35,428 for 15
minutes. Data were analyzed with GraphPad Prism 3.0 to obtain Kd, Ki and Bmax
values.

6. Immunocytochemistry and Confocal Microscopy
Immunocytochemistry and confocal microscopy was performed with COS7 cells. Cells were seeded on methanol treated coverslips in 6-well plates such
that they would be 40-80% confluent the next day. Polyfect reagent was used to
perform the transient transfections with the cDNA plasmids. Forty-eight hours
after transfection, the cells were washed thrice with PBS and fixed using 4%
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paraformaldehyde solution in PBS at room temperature for 15 minutes. The
fixed cells were washed three times with PBS and incubated with blockingpermeabilizing solution (5% goat serum, 0.5% BSA, 0.1% Triton X-100 in PBS
solution) for 45 minutes. The cells were next washed thrice with BSA buffer
(0.5% BSA solution in PBS) and incubated with rat monoclonal anti-DAT
antibody at 1:1000 dilution for 1 hour. After washing five times with BSA buffer to
remove the excess anti-DAT antibody, the cells were incubated with secondary
antibody (goat anti-rat Alexa Fluor 488) at 1:500 dilution and rhodamine
phalloidin at 1:250 dilution for 1 hour. When transfections were performed with
plasmids coding GFP, the antibody incubation steps were eliminated and cells
were incubated with rhodamine phalloidin at 1:250 dilution for 1 hour. After three
washes in BSA buffer and three washes in PBS, the coverslips were slightly airdried and mounted on slides using GVA mounting solution. The slides were left
in dark at 4 ºC overnight to dry completely. All the fluorophores were visualized
using a Leica TCS-SP2 confocal laser microscope with an oil immersion 100x
objective. Alexa 488 and GFP were excited at 488 nm with an argon/kypton
laser and emission photons from 500 – 600 nm were accumulated by the
photomultiplier tube.

Rhodamine phalloidin was excited at 543 nm with a

helium/neon laser and emission photons from 550 to 650 nm were accumulated.
The fluorophores were detected separately and overlay images were generated
automatically by the imaging software. In experiments where quantification of
the images was performed, 10 individual cells were selected randomly by
screening the whole slide. All scan related and in-line parameters except Z-level
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were fixed when acquiring images for each fluorophore. Images were quantified
using the histogram quantification tool of the Leica Confocal Software.

The

mean intensity values for ten different regions on the cell membrane having the
same number of pixels and area were obtained. The average intensity of the ten
different regions on the cell membrane was calculated and the mean intensity for
each fluorophore was determined by averaging the mean intensities of ten
different cells. For counting the number of cells transfected, ten different fields
were selected randomly by screening the whole slide using 20x objective.

7. Protein Assays
Protein assays were performed on CHO cells stably transfected with WT
DAT, and COS-7 and N2A cells transiently transfected with WT DAT. For all the
experiments that required protein content estimation, two wells were reserved for
determining the protein content. The protein assays were performed as follows:
the adherent cell monolayers were washed 2 x 1 ml with PBS, the cells were
lysed with 0.5 ml 0.2 N sodium hydroxide solution, gently scraped with a cell
scraper and incubated at 4ºC with gentle shaking for 1 hour. The cell lysates
were transferred into Eppendorf tubes and stored at -20ºC until the protein
content was estimated. All protein assays were performed using the Bradford
method. Bovine serum albumin (BSA; 1 mg/ml stock solution) was used as the
protein standard for generating the protein standard curve. Six different known
concentrations of protein were prepared by diluting 1, 2, 3, 4, 5 and 6 µl of BSA
stock solution to 800 µl with sterile water to achieve final concentrations of 1, 2,
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3, 4, 5 and 6 µg/ml respectively after the final addition of 200 µl BioRad reagent.
Tubes for the test samples were also prepared simultaneously by adding 20 µl
test sample to sterile water to obtain a final volume of 800 µl. Two hundred µl
BioRad reagent was then added to all the known and test sample tubes. The
tubes were vortexed for 10 seconds and incubated at room temperature for 10
minutes. The absorbance values were determined at 595 nm using UV-Visible
spectrophotometer.

Protein standard curve was obtained by plotting the

absorbance values of the known samples against the amount of protein in each
sample using Microsoft Excel. The amount of protein in each of the test samples
was calculated from the standard curve.

8. Statistics
Statistical significance was calculated using GraphPad Prism 3.0.
Statistical significance among three groups was determined using one-way
analysis of variance with Newman-Keuls post hoc test. Two-group comparisions
were made using a two-tail Student’s t test.
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IV. RESULTS
A. Effects of cell age and DAT cell surface expression on dopamine uptake
inhibition potencies of classical DAT ligands.
It was empirically observed for years that the DUIP of cocaine at WT DAT
was not static and changes in cocaine DUIP occurred within the same cell line
when assays were performed employing different passages of cells.

In an

attempt to address this issue, the present study investigated the effect of cell
state on DUIP fluctuation of cocaine and the trend this fluctuation follows with
increasing cell passage number. Different passages of stably transfected WT
DAT CHO cells were employed and passages 9 – 20, 25 – 36 and 40 – 54 were
classified as “low”, “medium” and “high” respectively. All uptake and binding
assays were performed in parallel and under identical conditions. A decrease in
the DUIP of cocaine at WT DAT was observed with increasing cell passage
number (Figure 5 and Table 1). The IC50 value for inhibition of [3H]-dopamine
uptake at low passage was about 2-fold less when compared to high passage
(Table 1). On the other hand, the apparent binding affinity of cocaine did not
vary with cell passage, evidenced by the unchanging Ki value from inhibition of
[3H]-WIN 35,428 binding assays (Figure 5 and Table 1). The study was further
expanded to test if this trend was exhibited by other classical DAT blockers.
Mazindol, methylphenidate and benztropine were the other DAT inhibitors tested
and a trend similar to cocaine for the DUIP was observed for these drugs with
cell passage (Table 1). The study also investigated if this property was exhibited
by DAT substrates such as (+)-amphetamine.

Interestingly, no significant

fluctuation in DUIP was observed for amphetamine (Figure 6 and Table 1).
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Similar to that of cocaine, the apparent binding affinities of the other DAT
blockers and amphetamine did not vary with cell passage (Table 1).

A

B

C

D

Figure 5. Cocaine and mazindol (DAT blockers) inhibition of [3H]-dopamine uptake and
[3H]-WIN 35,428 binding at WT DAT CHO cells.
Cocaine inhibition of [3H]-dopamine uptake (Panel A), cocaine inhibition of [3H]-WIN
35,428 binding (Panel B), methylphenidate inhibition of [3H]-dopamine uptake (Panel C) and
methylphenidate inhibition of [3H]-WIN 35,428 binding (Panel D) at different passages of WT DAT
CHO cells. Passages 9 – 20, 25 – 36 and 40 – 54 were classified as “low”, “medium” and “high”,
respectively. Uptake and binding experiments for each drug at different passages were
performed in parallel and under identical conditions. The data are representative of at least 3
independent experiments.
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The ratios of dopamine uptake inhibition potency-to-binding affinity for the
different DAT ligands at the different passages of WT DAT CHO cells were
calculated. (Table 2; Ki values (not shown) and IC50 values for [3H]-dopamine
uptake inhibition in Table 1 were essentially identical, allowing direct comparison
of uptake and binding inhibition constants).

A

B

Figure 6. (+)-Amphetamine (DAT substrate) inhibition of [3H]-dopamine uptake and [3H]WIN 35,428 binding at WT DAT CHO cells.
Amphetamine inhibition of [3H]-dopamine uptake (Panel A) and amphetamine inhibition of
3
[ H]-WIN 35,428 binding (Panel B) under identical conditions at different passages of WT DAT
CHO cells. Passages 9 – 20, 25 – 36 and 40 – 54 were classified as “low”, “medium” and “high”,
respectively. The data are representative of at least 3 independent experiments.
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Table 1. Dopamine uptake inhibition potencies and binding affinities of DAT ligands at WT
DAT CHO cells as a function of cell passage number.
IC50 and Ki values were derived from experiments incubating the stably-transfected cells
with nonradioactive DAT inhibitors in the presence of [3H]-dopamine and [3H]-WIN 35,428,
respectively, at 22ºC in KRH buffer. Passages 9 -20, 25 - 36 and 40 - 54 were classified as
“low”, “medium” and “high”, respectively. Mean ± SEM for at least 3 independent experiments.

Cell Passage
Low
[3H]-DA uptake

Medium

High

IC50 (nM)

inhibition
Cocaine

719 ± 94

1055 ± 52

1503 ± 127a

Mazindol

44 ± 4

74 ± 5

93 ± 17a

Methylphenidate

352 ± 17

640 ± 22

662 ± 45a

Benztropine

236 ± 40

395 ± 45

413 ± 27a

(+)-Amphetamine

671 ± 88

756 ± 86

906 ± 39

[3H]-WIN 35,428

Ki (nM)

inhibition
Cocaine

179 ± 22

197 ± 22

251 ± 28

Mazindol

15 ± 2

19 ± 2

20 ± 2

Methylphenidate

74 ± 7

72 ± 5

85 ± 6

Benztropine

78 ± 6

85 ± 9

92 ± 10

(+)-Amphetamine

524 ± 31

478 ± 52

557 ± 78

Kd (nM)

17 ± 1

17 ± 2

18 ± 1

Bmax (pmol/mg)

9±2

11 ± 2

19 ± 3a

[3H]-WIN 35,428 binding

a

P < 0.05 versus low passage cells for that assay (one-way ANOVA, Newman-Keuls post hoc
test)

53
[3H]-WIN 35,428 saturation binding assays demonstrated that there was
an increase in the surface expression of WT DAT in CHO cells with increasing
cell passage number, evidenced by the increased Bmax value for [3H]-WIN 35,428
binding at high passage cells. However, the binding affinity of [3H]-WIN 35,428
remained unchanged at the different cell passages (Table 1).

Table 2. Ratios of dopamine uptake inhibition potency-to-binding affinity for DAT ligands
at WT DAT CHO cells as a function of cell passage number.
Ratios were calculated using the IC50 values for inhibition of [3H]-dopamine uptake and Ki
values for inhibition of [3H]-WIN 35,428 binding in Table 1. Ki values (not shown) and IC50 values
for [3H]-dopamine uptake inhibition were essentially identical, allowing direct comparison of
uptake and binding inhibition constants.

DUIP:Affinity Ratio
Cell Passage
Low

Medium

High

Cocaine

4.0

5.3

5.9

Mazindol

2.9

3.8

4.7

Methylphenidate

4.8

8.8

7.8

Benztropine

3.0

4.6

4.5

(+)-Amphetamine

1.3

1.6

1.6

To address whether the decrease in DUIP of cocaine at high passage WT
DAT CHO cells was simply a result of increase in DAT levels, assays were
performed manipulating the cell density (% confluence) of WT DAT CHO cells.
The monolayer was defined as 100% confluent when all cells appeared to
contact neighboring cells so as not to leave open spaces on the culture plate.
Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding assays
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performed on 20%, 100% and 150% confluent monolayers suggested that cell
density had no effect on either cocaine DUIP or binding affinity (Reference:
Structural determinants for substrate and inhibitor recognition by the dopamine
transporter, Dissertation of Okechukwu T. Ukairo, Duquesne University).

To

further investigate the DUIP shift of cocaine, naive COS-7 cells were transiently
transfected with varying amounts of a cDNA plasmid encoding the WT DAT to
achieve different DAT expression levels with respect to individual cells. The
amounts of plasmid employed in the transfections were 25, 50 and 100% of what
is optimal.

[3H]-WIN 35,428 saturation binding analysis confirmed that Bmax

values shifted in accordance with manipulation of plasmid level (Table 3). Bmax
values reflect DAT expression at the cell surface as it has been shown that WIN
35,428 does not cross the plasma membrane of the intact cell appreciably (Chen
et al., 2004). The [3H]-dopamine uptake assays demonstrated that the DUIP of
cocaine differed significantly between cells transfected with 25% and 100% of
optimal plasmid levels while WIN 35,428 binding affinity remained unaffected
(Table 3). Confocal microscopic analysis further confirmed the changes in COS7 cell surface DAT expression observed in the binding experiments (Figure 7).
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Table 3. Dopamine uptake inhibition potency of cocaine and binding affinity of WIN 35,428
at COS-7 cells as a function of amount of WT DAT plasmid introduced.
Naive COS-7 cells were transiently transfected with 375 (25%), 750 (50%) or 1500
(100%) ng of WT DAT cDNA plasmid to manipulate the surface expression of DAT. [3H]-WIN
35,428 saturation binding assays were performed parallel to [3H]-dopamine uptake inhibition
assays and under identical conditions. Mean ± SEM for at least 3 independent experiments.

WT DAT Plasmid (% of Optimal)
25
[3H]-DA uptake

50

100

IC50 (nM)

inhibition
228 ± 7

353 ± 20

558 ± 75a

Kd (nM)

12 ± 2

15 ± 2

14 ± 2

Bmax (pmol/mg)

0.8 ± 0.4

2.0 ± 0.5

4.0 ± 0.2a

Cocaine
[3H]-WIN 35,428
binding

a

P < 0.05 versus low passage cells for that assay (one-way ANOVA, Newman-Keuls post hoc
test)
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Figure 7. Confocal microscopy of transiently transfected COS-7 cells.
COS-7 cells were transiently transfected with 25% or 100% of optimal WT DAT cDNA
plasmid levels. The expressed DAT protein was visualized with Alexa Fluor 488 (green signal;
Panels A and B) and cortical F-actin, a marker at the plasma membrane, was visualized with
rhodamine phalloidin (red signal; Panels C and D). Shown are representative confocal images of
three independent experiments. Cell membrane signal intensities were quantitated for each of
the four scenarios represented by Panels A – D (Panel E). Scale bar = 8.00 µm for all the
images. The data in Panel E represent an average of three independent experiments. *P<0.05
relative to DAT with 100% DNA.
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A

B

Figure 8. Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding at N2A
cells expressing varying levels of WT DAT.
Cocaine inhibition of [3H]-dopamine uptake (Panel A) and cocaine inhibition of [3H]-WIN
35, 428 binding (Panel B) under identical conditions at N2A neuroblastoma cells transiently
transfected with 375 (25%) or 1500 (100%) ng of WT DAT cDNA plasmid. The data are
representative of at least 3 independent experiments.

All the above experiments studying the DUIP fluctuations of DAT ligands
were performed in non-neuronal cell systems (CHO and COS-7). DAT is a
protein expressed in vivo in neuronal cells.

Therefore, to address the

physiological significance of the cocaine DUIP fluctuation phenomenon, a
neuronal cell line was tested. Naive N2A neuroblastoma cells were transiently
transfected with varying amounts of WT DAT cDNA plasmid. The amounts of
plasmid employed in the transfections were 25% and 100% of what is optimal.
Similar to the COS-7 cell experiment, cocaine DUIP was significantly altered by
the plasmid titration in N2A cells. The binding affinities for cocaine and WIN
35,428 were unaffected (Figure 8 and Table 4). Again, Bmax values from parallel
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WIN 35,428 saturation binding analysis indicated that DAT expression was
predictably shifted by the manipulation of plasmid level (Table 4).

Table 4. Dopamine uptake inhibition potency and binding affinity of cocaine at N2A
neuroblastoma cells as a function of amount of WT DAT plasmid introduced.
Naive N2A cells were transiently transfected with 375 (25%) or 1500 (100%) ng of WT
DAT plasmid to manipulate the surface expression of DAT. [3H]-WIN 35,428 binding assays were
performed parallel to the [3H]-dopamine uptake inhibition assays and under identical conditions.
Mean ± SEM for at least 3 independent experiments.

WT DAT Plasmid (% of Optimal)
25

100

IC50 (nM)
3

[ H]-DA uptake
inhibition
Cocaine

789 ± 64a

476 ± 46
Ki (nM)

3

[ H]-WIN 35,428
inhibition
Cocaine

229 ± 34

196 ± 11

Kd (nM)

25 ± 2

18 ± 3

Bmax (pmol/mg)

1.3 ± 0.4

2.8 ± 0.5a

[3H]-WIN 35,428 binding

a

P < 0.05 versus low passage cells for that assay (two-tail Student’s t test)
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B. Assessing the role of N- and C-terminus of DAT in the DUIP fluctuation
of cocaine.
Several proteins directly interact with and play an important role in the
trafficking and functioning of the DAT (reviewed in Torres, 2006). Differences in
the DAT brought about by protein interactions might be responsible for the
formation of two or more distinct conformations of the transporter and cocaine
may bind to these multiple DAT conformations with different affinities.

To

investigate the role of protein interactions of DAT in the DUIP fluctuation, N- and
C-terminal fragments of WT DAT were overexpressed in two cell systems that
showed the DUIP fluctuation, COS-7 and N2A. The N- or C-terminal fragments
of DAT may act as “decoys” by intercepting the DAT modulators and altering the
dopamine uptake and DUIPs of the DAT blockers. Studies in COS-7 cells were
carried out by co-expressing WT DAT and the N- or C-terminal fragments of WT
DAT. [3H]-dopamine uptake assays demonstrated that the N- and C-terminal
fragments of DAT did not exhibit any significant effect on the net dopamine
uptake at the DAT (Figure 9). Cocaine inhibition of [3H]-dopamine uptake and
cocaine inhibition of [3H]-WIN 35,428 binding assays demonstrated that
overexpression of the N- or C-terminal fragments of the DAT neither affected the
DUIP nor the binding affinity of cocaine at the DAT in a significant manner
(Figure 10 and Table 5). The overexpression of the DAT terminal fragments in
COS-7 cells was confirmed by confocal microscopy studies (Figure 11). Studies
in N2A neuroblastoma cell system were carried out by intentionally manipulating
the DAT cell surface expression and co-expressing the N- or C-terminal
fragments of the DAT with the WT DAT. Cocaine inhibition of [3H]-dopamine
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uptake assays demonstrated that the N- and C-terminal decoys employed in the
N2A neuroblastoma cell system do not show any significant change in the DUIP
of cocaine at the different DAT expression levels (Figure 13 and Table 6).

Figure 9. [3H]-Dopamine uptake at DAT in the presence of N- or C-terminal fragments of
DAT.
Specific [3H]-dopamine uptake as a percentage of WT DAT was measured in COS-7 cells
transiently co-transfected with WT DAT and control vector (blue) or N- (green) or C- (yellow)
terminal fragments of WT DAT. The N- and C-terminal fragments of DAT are abbreviated as NT
and CT respectively. The data represent an average of three independent experiments.
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A

B

Figure 10. Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding at DAT
in the presence of N- or C-terminal fragments of DAT.
Cocaine inhibition of [3H]-dopamine uptake (Panel A) and cocaine inhibition of [3H]-WIN
35, 428 binding (Panel B) performed in parallel and under identical conditions in COS-7 cells
transiently co-transfected with 750 ng WT DAT and 750 ng control vector (squares) or N(triangles) or C- (circles) terminal fragments of WT DAT. The N- and C- terminal fragments of
DAT are abbreviated as NT and CT respectively. The data are representative of at least three
independent experiments.

Table 5. Effect of overexpression of N- or C-terminal fragments of DAT on the DUIP and
binding affinity of cocaine at DAT.
Cocaine inhibition of [3H]-dopamine uptake and cocaine inhibition of [3H]-WIN 35,428
binding assays were performed in parallel and under identical conditions in COS-7 cells
transiently co-transfected with WT DAT and control vector or N- or C-terminal fragments of WT
DAT. Mean ± SEM for at least 3 independent experiments.

DAT

DAT+NT

DAT + CT

Cocaine
IC50 (nM)
[3H]-Dopamine uptake

474 ± 54

504 ± 40

512 ± 36

inhibition
Ki (nM)
[3H]-WIN 35,428 inhibition

206 ± 29

209 ± 38

256 ± 74
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Figure 11. Confocal microscopic localization of DAT N- and C-terminal fragments.
COS-7 cells were transiently co-transfected with WT DAT and control vector or N- or Cterminal fragment of DAT. The expressed N- or C-terminus fragment proteins were visualized
with the attached GFP tag (green signal) and cortical F-actin, a marker at the plasma membrane,
was visualized with rhodamine phalloidin (red signal). The fluorophores were detected separately
and overlay images were generated. Scale bar = 8.00 µm for all the images. Shown are
representative confocal images of three independent experiments.

Untransfected
cells

GFP vector

DAT C-terminal
fragment

DAT N-terminal
fragment

GFP

F-actin

Overlay
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Figure 12. Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding at DAT
in the presence of N- or C-terminal fragments of DAT.
Cocaine inhibition of [3H]-dopamine uptake in N2A cells transiently co-transfected with
200 (25%, Panel A) or 1000 (100%, Panel B) ng WT DAT and 500 ng control vector (squares) or
N- (triangles) or C- (circles) terminus fragments of WT DAT. All uptake experiments were
performed under identical conditions. The data are representative of at least three independent
experiments.

Table 6. Effect of overexpression of N- or C-terminal fragments of DAT on the DUIP and
binding affinity of cocaine at DAT.
Cocaine inhibition of [3H]-dopamine uptake in N2A cells transiently co-transfected with
varying amounts of WT DAT and control vector or N- or C-terminal fragments of WT DAT. All the
uptake experiments were performed under identical conditions and on the same day. Mean ±
SEM for at least 3 independent experiments.

DAT

DAT+NT

DAT + CT

IC50 (nM)
25% DAT DNA

336 ± 34

420 ± 36

326 ± 57

100% DAT DNA

593 ± 124

624 ± 76

682 ± 76
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Another possibility for the DUIP fluctuation in the present study could be a
change in the phophorylation state of the DAT. Studies have shown that the DAT
is N-terminally phosphorylated (Foster et al., 2002, Granas et al., 2003) and
phosphorylation can affect the cell surface trafficking of the transporter (Holton et
al., 2005). To test if the N-terminal phosphorylation plays any role in the DUIP
shift of cocaine, inhibition of [3H]-dopamine uptake and inhibition of [3H]-WIN
35,428 binding assays were performed in COS-7 cells expressing human DAT
(hDAT) and hDAT lacking the first 20 amino acids (del-20 hDAT). No significant
difference was observed in the DUIP of cocaine at hDAT compared to the Nterminal truncated hDAT (Figure 13 and Table 7). Studying the dopamine uptake
at del-20 hDAT was another approach to assess the role of N-terminus of the
DAT in the DUIP fluctuation.

A

B

Figure 13. Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding at
hDAT and del-20 hDAT.
Cocaine inhibition of [3H]-dopamine uptake (Panel A) and [3H]-WIN 35,428 binding (Panel
B) under identical conditions at hDAT (squares) and del-20 hDAT (circles) transiently transfected
in COS-7 cells. The data are representative of 3 independent experiments.
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Table 7. Effect of N-terminal truncation on the DUIP and binding affinity of cocaine at
hDAT.
Cocaine inhibition of [3H]-dopamine uptake and [3H]-WIN 35,428 binding performed in
parallel and under identical conditions at hDAT and del-20 hDAT transiently transfected in COS-7
cells. Mean ± SEM for at least 3 independent experiments.

hDAT

del-20 hDAT

Cocaine
IC50 (nM)
3

[ H]-Dopamine uptake

214 ± 56

183 ± 30

inhibition
Ki (nM)
[3H]-WIN 35,428 inhibition

799 ± 139

666 ± 115
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V. DISCUSSION
A number of studies have demonstrated that the DUIPs of the classical
DAT blockers do not correlate well with their apparent binding affinities at the WT
DAT. These DAT blockers are more potent in inhibiting [3H]-WIN 35,428 binding
than in inhibiting [3H]-dopamine uptake (Pristupa et al., 1994; Eshleman et al.,
1999; Wang et al., 2003). In the present study, the DUIPs of cocaine, mazindol,
methylphenidate and benztropine followed a decreasing trend with increasing cell
passage; statistically significant differences in the DUIPs were observed between
the low and high passages while their binding affinities remained unchanged in
WT DAT CHO cells. Neither the DUIP nor the binding affinity of amphetamine
(DAT substrate) fluctuated at the different passages (Table 1).

The loss of

correlation between DUIP and binding affinity at DAT might be a unique property
of DAT blockers that is not exhibited by DAT substrates.

Besides being a

substrate at the DAT, amphetamine has the ability to induce dopamine efflux via
the DAT by reversal of the transporter (reviewed in Kahlig and Galli, 2003). It
has been shown that amphetamine can cause dopamine efflux in dopamine
preloaded COS-7 cells (transfected with WT DAT cDNA plasmid), and cocaine
and other DAT blockers either inhibit or have no effect on the dopamine release
in these cells (Eshleman et al., 1994; Pifl et al., 1995). Thus, DAT blockers differ
from DAT substrates in several respects.
The ratios of dopamine uptake inhibition potency-to-binding affinity for
DAT ligands further demonstrate the differences in the behavior of amphetamine
and the tested DAT blockers at WT DAT CHO cells as a function of cell passage
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number (Table 2). The dopamine uptake inhibition Ki value of amphetamine was
not significantly different from its binding affinity Ki value at WT DAT, evidenced
by the near unity (1.3 – 1.6) uptake inhibition potency:binding affinity ratios. On
the other hand, the dopamine uptake inhibition Ki values of DAT blockers were
significantly different from their binding affinity Ki values at WT DAT (uptake
inhibition potency:binding affinity ratios ranged from 2.9 – 8.8 for different DAT
blockers at the different passages). Moreover, these ratios were comparably
different for DAT blockers at low versus high passage WT DAT CHO cells;
amphetamine did not exhibit such differences.

Thus, two inferences can be

drawn from the above observations: a) amphetamine is equipotent in inhibiting
dopamine uptake and WIN binding at WT DAT while DAT blockers are not b) the
uptake inhibition profile of DAT blockers is comparably different at low and high
passage WT DAT CHO cells, a phenomenon that does not occur with
amphetamine.

However, this differential behavior of DAT blockers and DAT

substrates at DAT in terms of uptake inhibition potencies needs further
investigation by employing other DAT substrates such as methamphetamine and
3,4-methylenedioxymethamphetamine (MDMA).
Contrary to the studies that have shown that DAT expression in the brain
decreases with aging (Bannon and Whitty, 1997; Salvatore et al., 2003), the
saturation binding experiments in the present study demonstrated increasing
DAT surface expression with increasing cell passage (Table 1). However, the
binding affinity of [3H]-WIN 35,428 remained unaffected, an observation in
agreement with the previous reports demonstrating unchanging binding affinities
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of DAT blockers despite changes in DAT surface expression (Shimizu and
Prasad, 1991; Hebert et al., 1999). In another study, altering the cell density (%
confluence) by over 7-fold to manipulate the total number of DAT molecules in
each well of the culture dish neither affected the DUIP nor the binding affinity of
cocaine (Reference: Structural determinants for substrate and inhibitor
recognition by the dopamine transporter, Dissertation of Okechukwu T. Ukairo,
Duquesne University).

Cocaine treatment increases DAT surface expression

(Little et al., 2002; Daws et al., 2002) and amphetamine exposure decreases
DAT surface expression (Gulley et al., 2002; Saunders et al., 2000; Zahniser and
Sorkin, 2004). These inhibitor- or substrate-mediated changes in DAT surface
expression would be irrelevant here because the present study employed drug
concentrations that were not high enough and drug incubations that were not
long enough to cause such changes.

Three µM amphetamine exposure

increased surface DAT levels within 1 minute, followed by rapid reversion to
normal levels (Johnson et al., 2005). This event may or may not be relevant to
the present experiments, in which amphetamine incubations were performed for
10 minutes. Therefore, the potency fluctuation observed with the DAT blockers
was not a direct consequence of changes in DAT surface expression. Some sort
of cell age-related DAT modification might play a significant role in the DUIP
fluctuations of the DAT blockers.
Considering the DUIP fluctuation of cocaine with cell passage/state, it is
unlikely that a single cocaine binding site of the DAT dictates dopamine uptake
inhibition. However, no solid evidence exists for two different binding sites for a
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single DAT ligand on the same DAT protein. Previous studies provide evidence
for the existence of DAT in more than one conformation or population. The DAT
conformation or population responsible for high affinity binding of DAT blockers
may be less responsible for dopamine uptake (Wang et al., 2003; Ukairo et al.,
2005). Distribution of the DAT conformations can be altered by DAT mutation
(Loland et al., 2002).

Similarly, the distribution of the different DAT

conformations or populations may be influenced by cell state, possibly by
alterations in their trafficking to the cell surface. A plausible explanation for the
loss of correlation between potency and apparent binding affinity of DAT
blockers, and DUIP fluctuations with cell passage observed in the present study
is the existence of two different DAT populations on the cell surface (twopopulation model; Wang et al., 2003).

Of the two different populations,

“Population 1” has a higher affinity for inhibitor binding but is less responsible for
dopamine uptake. On the contrary, “Population 2” has a lower affinity for inhibitor
binding but is largely responsible for dopamine uptake (Figure 14). The DAT
blocker has to bind to Population 2 (lower DAT blocker affinity), a population
underrepresented in binding experiments, to inhibit dopamine uptake. Binding
experiments largely represent Population 1 (higher DAT blocker affinity). Hence,
the [3H]-dopamine uptake inhibition IC50 values are higher than the inhibition of
[3H]-WIN 35,428 binding Ki values at the DAT (Table 1).

Extending this

discussion to the cell passage-related DUIP fluctuation of DAT blockers, the
surface expression of Population 2 increases with cell passage while surface
expression of Population 1 remains unaltered; net surface DAT levels are
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increasing. In addition to these surface expression changes, the DAT inhibitor
affinity at Population 2 decreases further with cell age (certain intracellular factors
may be involved); the net result being a shift in the DUIP of DAT blockers at
higher passage without any change in their binding affinities. This model also
resolves the observation that the binding affinity (Kd) of WIN 35,428 remains
unaltered despite changes in surface expression in the saturation binding
experiments (Table 1).

Studies have consistently demonstrated unchanging

binding affinity with increasing DAT surface expression (Shimizu and Prasad,
1991; Hebert et al., 1999). The differences in binding sites of DAT blockers and
substrates and the fact that amphetamine also acts as a substrate at DAT might
form the basis for the divergent behavior of DAT blockers and amphetamine with
respect to potency fluctuation.

Amphetamine-mediated reversal of the

transporter, a characteristic property not exhibited by the DAT blockers, may
have an influence on the number of transporter molecules available for dopamine
uptake or on the DUIP of amphetamine. The fact that amphetamine (a DAT
substrate) displaced [3H]-WIN 35,428 (a DAT blocker) in binding assays needs to
be considered before elucidating the divergent behavior of amphetamine from
the DAT blockers tested.
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DAT Population 1
Higher WIN affinity

DAT Population 2
Lower WIN affinity

WIN

WIN

WIN

Figure 14. Two population model of the DAT.
Population 1 (blue) displays a higher affinity for WIN 35,428 (green) but is less
responsible for dopamine uptake. Population 2 (pink) displays a lower affinity for WIN 35,428 but
is largely responsible for the dopamine uptake. WIN 35,428 has to bind to Population 2 to inhibit
dopamine uptake. Thus, uptake inhibition experiments principally represent Population 2.
Binding experiments largely represent Population 1. Reproduced from Wang et al.,2003.

To mimic the cell passage-related changes in surface expression
observed in WT DAT CHO cells, naive COS-7 cells were transfected with
different amounts of a cDNA plasmid encoding the WT DAT. Thus, manipulation
of DAT surface expression in individual cells was attempted.

Indeed, a

significant decrease in Bmax was observed when a 4-fold lower amount of DNA
was employed (Table 3). Interestingly, the DUIP shift for DAT blockers (similar to
that observed with different passages of WT DAT CHO cells) correlated with
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altered DAT surface expression in the COS-7 cells. Consistent with the previous
results, the binding affinity remained static. Quantitative confocal microscopy
further confirmed the changes in DAT surface expression (Figure 7). Similar
experiments were performed in N2A neuroblastoma cells to test the physiological
relevance of the DUIP shift. The DUIP fluctuation phenomenon extended to the
neuronal cell line studied (Table 4).
As

briefly

posttranslational

mentioned
DAT

earlier,

modification

intracellular

pattern

or

events

DAT

(e.g.,

homo-

or

altered
hetero-

oligomerization) might be controlling the relative distribution of the DAT
populations (responsible for the DUIP fluctuations of DAT blockers at DAT).
Physiological changes in the cell cause variations in the glycosylation patterns of
proteins (Lis and Sharon, 1993; Patel et al., 1994). N-glycosylation of the DAT
increased the DUIPs of cocaine-like drugs without affecting their binding affinities
(Li et al., 2004). Thus, a slightly different pattern of posttranslational modification
of DAT can lead to the expression of more than one population of transporters in
the cell. DAT homo-oligomerization state affects transporter function and DAT
ligands can modify this state (Sorkina et al., 2003; Hastrup et al., 2003).
Several proteins have been implicated in DAT-protein interactions and
these protein interactions influence the cell surface expression or function of the
DAT (reviewed in Torres, 2006).

Synuclein and PICK1 interact with the C-

terminal region of the DAT resulting in increased DAT surface expression and
increased dopamine uptake. Hic-5 interacts with the amino-proximal portion of
the intracellular carboxyl terminus of DAT and overexpression of this protein
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downregulates DAT uptake activity by decreasing the DAT surface expression.
Syntaxin 1A and RACK1 interact with the N-terminal region of the DAT but the
effects of these interactions on DAT surface expression and function have not yet
been established. Syntaxin 1A interacts with the N-terminal region of the GAT1
and the NET, and modulates surface expression and transport activity (Deken et
al., 2000; Horton and Quick, 2001; Sung et al., 2003; Hansra et al., 2004).
Therefore, it is likely that syntaxin 1A also plays a significant role in regulating the
activity and/or trafficking of the DAT (GAT1 and NET belong to the same family
of transporters to which DAT belongs).

Alterations brought about by protein

interactions with the DAT may be responsible for the formation of different DAT
populations and cocaine may bind to these dissimilar DAT populations with
different affinities. In order to test whether intracellular factor interactions with the
DAT N- or C-terminus was related to the DUIP fluctuations, GFP fusion
polypeptides of the DAT N- or C-terminal fragments were coexpressed with WT
DAT in COS-7 cells. The DAT fragments were intended to serve as “decoys” by
intercepting the DAT modulators responsible for the DUIP shifts. Overexpression
of the N- or C-terminal decoys did not affect the net dopamine uptake and DUIP
of cocaine at DAT significantly (Figure 9 and Table 5). The confocal images
provided evidence for overexpression of the decoys in the cells (Figure 11). A
decoy comprised of the region of the DAT from the beginning of the N-terminus
to the end of the second transmembrane domain that decreased the DAT uptake
activity by some unknown mechanism was employed as a positive control (not
shown) in all the experiments. Thus, the DAT N- or C-terminal interactions with
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intracellular proteins do not appear to be responsible for the DUIP shift in COS-7
cells. The level of expression of a given DAT-modulating protein may depend on
the cell type. To test the possibility of DAT termini-protein interactions, another
cell system N2A neuroblastoma (that showed the DUIP fluctuation) was
employed. This time the DAT surface expression was intentionally manipulated
(four-fold) to begin with a cell system that already showed the DUIP fluctuation
before assessing the effect of overexpression of the decoys.

If protein

interactions at the DAT termini are responsible for the fluctuation, the decoy
overexpression would shift the DUIP of cocaine at one of the expression levels
such that it equals the DUIP at the other expression level.

No significant

differences were observed in the DUIP of cocaine by overexpression of the
decoys. Thus, DAT N- or C-terminal interactions with intracellular proteins do not
appear to account for the DUIP shift in N2A cells. Another approach for future
studies would be to overexpress a given DAT interacting factor in a DAT-bearing
cell system to test for DUIP shifts.
Another possibility for the DUIP fluctuation in the present study could be a
change in the phosphorylation state of the DAT. The N-terminal region of the
DAT possesses multiple sites for phosphorylation (Foster et al., 2002; Granas et.
al 2003; Lin et al., 2003). Deletion of the first 22 N-terminal residues, which
included the terminal five serines, abolished detectable hDAT phosphorylation
(Granas et al., 2003).

Additionally, dopamine uptake in mouse striatum was

significantly affected by a wide-spectrum inhibitor of protein kinases (Simon et
al., 1997). A change in the phosphorylation state of the DAT may result in the
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existence of cell surface DAT in two or more conformations or populations with
different phosphorylation states which may affect the ability of cocaine to bind to
the transporter. The hDAT mutant, del-20 hDAT, employed in the present study
lacks the first 20 amino acids including the five N-terminal serines that have been
demonstrated to be the most important residues in DAT phosphorylation.
Removal of these serines did not affect the DUIP of cocaine (Table 7). Thus, the
N-terminal phosphorylation of DAT, specifically involving the first five serines, is
not associated with the DUIP shift.

However, other serine and threonine

residues are present in the DAT sequence; the role of phosphorylation in creating
distinct DAT populations cannot be totally ruled out. Phosphorylation can occur
at any of the serine or threonine residues in the DAT that are exposed to the
intracellular compartment.

To completely assess the role of phosphorylation

state of DAT in DUIP fluctuations, DAT mutants with N-terminal truncations
lacking the other N-terminal serines and threonines, C-terminal truncations and
point mutants at the serines and threonines in the intracellular loops should be
employed.
Further studies investigating the occurrence and regulation of the different
DAT populations or conformations and their association with the DUIP shifts may
help identify the factors influencing the DAT activity, which in turn may identify
targets for anti-cocaine and anti-amphetamine therapeutics.
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